Intravenous Immunoglobulin (IVIG) Market Growth Analysis By Industry Revenue & Top Key Players Baxter International, CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma, LFB group, Biotest AG and Many Others

The major factors that drive the growth of the IVIG market include increase in geriatric population, surge in the number of hemophilic patients, rise in production of immunoglobulin due to the emergence of advanced technologies, and advent of enhanced purification techniques for better plasma yield. Furthermore, surge in prevalence diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP), hypogammaglobulinemia, and others are expected to boost the market growth. However, stringent government regulations toward IVIG products and high risk of side effects associated with the use of IVIG are expected to hamper the growth of the market. On the contrary, technological advancements in IVIG products are expected to provide lucrative opportunities to the market in near future.

The global intravenous immunoglobulin (IVIG) market was valued at $7,861 million in 2015 and is projected to reach $12,632 million by 2022, registering a CAGR of 7.1% from 2016 to 2022.

Download [PDF] Report Sample @ https://www.alliedmarketresearch.com/request-sample/325

Immunoglobulin (IG) is a plasma-derived product, which is obtained from the serum of healthy donors. The isolated plasma product is clinically treated and purified to IG, which can be further used in the treatment of patients with antibody deficiency. Intravenous immunoglobulin (IVIG) is used in various fields such as hematology, immunology, neurology, dermatology, nephrology, ophthalmology, and rheumatology.

The prevalence of a host of antibody deficiency disorders such as common variable immune deficiency (CVID), specific antibody deficiency, and hypogammaglobulinemia, increase in immunoglobulin indications, improved production & purification processes, growth in awareness toward antibody deficiency, and rare immune disorders among patient population drive the growth of the global IVIG market. However, stringent government regulations towards immunoglobulin products and high risk of side effects owing to the use of intravenous immunoglobulin are expected to hamper the growth of the market.

Based on application segment, hypogammaglobulinemia held the largest market share in 2015 and is anticipated to continue this trend in near future. Large patient population, lack of effective substitute treatment, and early adoption of immunoglobulin for the treatment of hypogammaglobulinemia are expected to boost the growth of this segment.

The key companies profiled in the report include

• Baxter International Inc;
• CSL Ltd.,
• Grifols, S.A.;
• Octapharma AG,
• Kedrion Biopharma Inc.,
• LFB Group,
• Biotest AG,
• China Biologics Products, Inc.;
• Shire (Baxalta); and
• Bayer AG.

Other players in the value chain include Hualan Biological Engineering Inc., Omrix Biopharmaceuticals Ltd., Behring GmbH, Shanghai RAAS Blood Products Co., Ltd., Option Care Enterprises, Inc., ADMA Biologics, Inc., and BioScrip, Inc.

Get Customized Report @ https://www.alliedmarketresearch.com/request-for-customization/325

Table Of Content

Chapter: 1. INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS:
1.3. KEY MARKET SEGMENTS:
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst tools and models

Chapter: 2. EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE

Chapter: 3. MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. OVERVIEW OF IVIG
3.2.1. Patented products
3.3. EPIDEMIOLOGY AND ECONOMIC BURDEN OF CHRONIC CONDITIONS
3.4. COST OF SIDE EFFECTS DUE TO IVIG TREATMENTS
3.5. KEY FINDINGS
3.5.1. Top Factors Impacting global IVIG market
3.5.2. Top Investment Pockets Global IVIG Market
3.6. PORTERS FIVE FORCES ANALYSIS
3.6.1. Bargaining power of buyers (Low)
3.6.2. Bargaining power of suppliers (Low)
3.6.3. Threat of new entrants (low)
3.6.4. Threat of substitutes (low)
3.6.5. Intense competitive rivalry (moderate)
3.7. VALUE CHAIN ANALYSIS
3.7.1. Primary activities
3.7.2. Support Activities
3.8. MARKET SHARE ANALYSIS (2014)
3.9. PRODUCT SCENARIO IN IVIG MARKET
3.10. GOVERNMENT REGULATIONS AND REIMBURSEMENTS
3.10.1. IVIG regulations in United States and Europe
3.10.2. Reimbursements Scenario
3.11. INDICATIONS FOR IVIG
3.11.1. USFDA Indications
3.11.2. EMA
3.12. COMPONENT ANALYSIS OF IMMUNOGLOBULIN G (IGG)
3.12.1. IgG1
3.12.2. IgG2
3.12.3. IgG3
3.12.4. IgG4
3.13. CLINICAL TRIALS
3.15. MARKET DYNAMICS
3.15.1. Drivers
3.15.2. Restraints
3.15.3. Opportunities

Access Full Summery @ https://www.alliedmarketresearch.com/press-release/intravenous-immunoglobulin-IVIG-market.html

About us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.